| HOME >> BIOLOGY >> TECHNOLOGY |
LIVINGSTON, N.J., Oct. 2 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that it has acquired additional patent rights with respect to painless anesthetic injections -- specifically rights related to controlling the flow rate or pressures used in providing these injections -- through issuance of 260,000 shares of restricted common stock. In connection with this acquisition, Milestone also agreed to terminate its Declaratory Judgment action against Dr. Milton Hodosh related to claimed infringements of his patent rights and Dr. Hodosh agreed to terminate his existing infringement action against the Company. Each party is responsible for their own attorney fees.
Joe Martin, Chief Executive Officer of Milestone, stated, "We are pleased to have acquired these additional patent rights, which strengthens our position as the dominant leader of advanced technology for administering painless anesthetic injections without expending any of our cash resources. Also, the related settlement of our Declaratory Judgment action against Dr. Hodosh and his infringement action against us eliminates further legal expense."
About Milestone Scientific Inc.
Headquartered in Livingston, New Jersey, Milestone Scientific is
engaged in pioneering proprietary, highly innovative technological
solutions for the medical and dental markets. Central to the Company's IP
platform and product development strategy is its patented CompuFlo(R)
technology for the improved and painless delivery of local anesthetic.
Specifically, CompuFlo is a computer-controlled, pressure sensitive
infusion, perfusion, suffusion and aspiration technology, which provides
real-time readouts of pressures, fluid densities and flow rates, enabling
the advanced delivery and removal of a wide array of fluids. The STA(TM)
(Single Tooth Anesthesia) System computer-controlled local anesthesia
delivery s
'/>"/>
| SOURCE Milestone Scientific Inc. Copyright©2008 PR Newswire. All rights reserved |